
    
      Demonstration of the superiority in terms of 4-year event-free survival (EFS) of Rituximab
      maintenance therapy compared to post-autograft surveillance in patients aged 18-65 years
      inclusive, treated with R-DHAP then autologous transplantation for MCL as first-line therapy.
    
  